All Pfizer published press releases by date and/or category of news
10.19.2021 Research Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress 09.29.2021 Research Vaccines Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released 09.28.2021 Research Vaccines Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate 09.28.2021 Covid-19 Research Vaccines Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age 09.27.2021 Research Vaccines Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program 09.27.2021 Covid-19 Research Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults 09.20.2021 Covid-19 Research Vaccines Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years 09.17.2021 Research Astellas’ and Pfizer’s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study 09.09.2021 Medicines Research Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis 09.02.2021 Research Vaccines Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV) 08.30.2021 Medicines Research Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis 08.04.2021 Medicines Research Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
A collection of assets for use by media.
The latest news from Pfizer and its strategic partners
09.20.2022 Corporate Partnerships CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development 06.21.2022 Corporate Partnerships Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.